Halda Therapeutics

About Halda Therapeutics

Halda Therapeutics is focused on developing RIPTAC™ therapeutics, a new class of precision medicines aimed at defeating cancer through innovative drug modalities.

Products & Services

RIPTAC™ Therapeutics:A novel class of precision medicines that use a 'hold-and-kill' mechanism to target tumor-specific proteins and essential functions, resulting in selective killing of cancer cells.

HLD-0915:A therapeutic under evaluation in Phase 1/2 clinical trials for metastatic castration-resistant prostate cancer.

Specialties

Precision Medicine Cancer Therapeutics RIPTAC™ Technology Drug Innovation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B extension T: - FT: Series B extension	A: 126000000 MR: - FA: 126 million FAN: 126000000	D: 2024-08-12 FD: 2024-08-12	10 investors

Series B extension Latest

2024-08-12

$126.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Christian Schade

PRESIDENT AND CEO, DIRECTOR

LinkedIn (Pro only)

K

Kat Kayser-Bricker

Chief Scientific Officer

S

Scott Phillips

Chief Financial Officer

E

Eyal Attar

Chief Medical Officer

C

Craig Crews

Professor of Molecular, Cellular, and Developmental Biology, Yale University

T

Tim Shannon

Board Chair

View 11 more team members with Pro

Unlock Full Team Directory

Recent News